| Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG … H Goldschmidt, EK Mai, U Bertsch, R Fenk, E Nievergall, D Tichy, ... The Lancet Haematology 9 (11), e810-e821, 2022 | 50 | 2022 |
| Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial LB Leypoldt, B Besemer, AM Asemissen, M Hänel, IW Blau, M Görner, ... Leukemia 36 (3), 885-888, 2022 | 50 | 2022 |
| Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG … H Goldschmidt, EK Mai, E Nievergall, R Fenk, U Bertsch, D Tichy, ... Blood 138, 463, 2021 | 31 | 2021 |
| Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG … K Weisel, AM Asemissen, B Besemer, M Haenel, IW Blau, M Goerner, ... Journal of Clinical Oncology 38 (15_suppl), 8508-8508, 2020 | 30 | 2020 |
| Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma LB Leypoldt, D Tichy, B Besemer, M Hänel, MS Raab, C Mann, M Munder, ... Journal of Clinical Oncology 42 (1), 26, 2024 | 12 | 2024 |
| Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II … K Weisel, AM Asemissen, A Schieferdecker, B Besemer, M Zago, C Mann, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e17, 2019 | 11 | 2019 |
| Downregulation of miR-503 in Activated Kidney Fibroblasts Disinhibits KCNN4 in an in Vitro Model of Kidney Fibrosis JH Christoph Mann, Brajesh Pratap Kaistha, Michael Kacika, Thorsten Stiewe Kidney Blood Press Res 44 (1), 2019 | 10 | 2019 |
| Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma: Planned interim analysis of the GMMG-Concept Trial K Weisel, B Besemer, M Haenel, R Lutz, C Mann, M Munder, M Goerner, ... Blood 140 (Supplement 1), 1836-1838, 2022 | 8 | 2022 |
| Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells EKM Mack, S Hartmann, P Ross, E Wollmer, C Mann, A Neubauer, ... Annals of Hematology 101 (4), 811-824, 2022 | 8 | 2022 |
| Updated interim analysis of the gmmg-concept trial investigating isatuximab, carfilzomib, lenalidomide, and dexamethasone (isa-krd) in front-line treatment of high-risk … L Leypoldt, B Besemer, AM Asemissen, M Hänel, IW Blau, M Görner, ... ONCOLOGY RESEARCH AND TREATMENT 44, 20-21, 2021 | 8 | 2021 |
| Real-world analysis of teclistamab in 123 RRMM patients from Germany C Riedhammer, F Bassermann, B Besemer, M Bewarder, F Brunner, ... Leukemia, 1-7, 2024 | 5 | 2024 |
| Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with isatuximab, carfilzomib, lenalidomide and dexamethasone … AM Asemissen, S Autenrieth, K Bieber, C Gouttefangeas, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e141-e142, 2019 | 4 | 2019 |
| Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation D Christen, K Sohlbach, SK Metzelder, E Wollmer, HG Hoeffkes, ... Leukemia & lymphoma 60 (8), 2056-2061, 2019 | 3 | 2019 |
| Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a … EK Mai, H Goldschmid, K Miah, U Bertsch, B Besemer, M Hänel, ... The Lancet Haematology 11 (2), e101-e113, 2024 | 2 | 2024 |
| Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany C Riedhammer, F Bassermann, B Besemer, M Bewarder, F Brunner, ... Blood 142, 3329, 2023 | 2 | 2023 |
| Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM K Kriegsmann, C Manta, R Schwab, EK Mai, MS Raab, HJ Salwender, ... Blood Advances 7 (3), 379-383, 2023 | 1 | 2023 |
| OA-43 Analysis of sustained MRD-negativity and progression-free survival of Isa-KRd in high-risk newly diagnosed multiple myeloma–additional data from planned interim analysis … L Leypoldt, D Tichy, B Besemer, M Hänel, M Raab, C Mann, M Munder, ... Clinical Lymphoma Myeloma and Leukemia 23, S26-S27, 2023 | | 2023 |
| P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS … EK Mai, U Bertsch, R Fenk, D Tichy, B Besemer, J Dürig, R Schroers, ... HemaSphere 6, 820-821, 2022 | | 2022 |
| Depth of response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in front-line induction of high-risk Multiple Myeloma: Interim analysis of the GMMG … KC Weisel, AM Asemissen, L Leypoldt, B Besemer, M Haenel, IW Blau, ... ONCOLOGY RESEARCH AND TREATMENT 43 (SUPPL 4), 91-92, 2020 | | 2020 |
| Mobilization of autologous stem cells under induction therapy with Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone (Isa-KRd) in high risk myeloma patients: First results … AM Asemissen, C Scheid, L Leypoldt, A Schieferdecker, B Besemer, ... Oncol. Res. Treat. 43 (SUPPL 4), 94-96, 2020 | | 2020 |
